Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.
about
Management of acute right ventricular failure in the intensive care unitSafety of sildenafil in infants*.Sildenafil and bosentan plasma concentrations in a human immunodeficiency virus- infected patient with pulmonary arterial hypertension treated with ritonavir-boosted protease inhibitorOverview of current therapeutic approaches for pulmonary hypertension.Pharmacokinetics of intravenous sildenafil in children with palliated single ventricle heart defects: effect of elevated hepatic pressures.Sildenafil in pediatric pulmonary arterial hypertension.Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgeryPulmonary hypertension-"state of the art" management in 2012.Sildenafil exposure and hemodynamic effect after Fontan surgeryIntensive care unit management of patients with severe pulmonary hypertension and right heart failure.Managing an acutely ill patient with pulmonary arterial hypertension.Paediatric pulmonary hypertension and sildenafil: current practice and controversies.Sildenafil for the treatment of pulmonary hypertension in children.Pulmonary hypertension and its management in patients undergoing non-cardiac surgery.Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.New pharmacotherapy options for pulmonary arterial hypertension.Pharmacokinetics of sildenafil in children with pulmonary arterial hypertension.Evaluation of the Tolerability of Intermittent Intravenous Sildenafil in Pediatric Patients With Pulmonary Hypertension.Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.A Phase I study to determine the pharmacokinetic profile, safety and tolerability of sildenafil (Revatio® ) in cardiac surgery: the REVAKI-1 study.Effects of tadalafil administration on plasma markers of exercise-induced muscle damage, IL6 and antioxidant status capacity.Evaluating the safety of intermittent intravenous sildenafil in infants with pulmonary hypertension.[Pulmonary hypertension : What is new in therapy?].Management von Patienten mit pulmonaler Hypertonie
P2860
Q34479233-C3431846-B988-415F-9D81-3BC14EC606CAQ35105255-8BB0227B-B5B4-4F72-B31F-D595D5BF5FBEQ35290066-624C2DE0-8B27-4A6E-8759-0AAB818E7107Q35412362-247B34D2-FF56-447E-BC95-2BCBC7D67996Q36113640-9997477E-F39E-4031-8C75-146A926BEC14Q37091197-DE8E9428-8EF6-4CA1-B13C-B1EA1488F309Q37195645-25D369B9-A61D-410A-AE31-280345329A93Q37387305-D42598E4-FCD1-43E6-ABE5-2977811C6B0AQ37460315-99D78B89-6D18-49FB-8AFC-812785B00BE3Q37893845-68749456-9C5F-4800-A452-79E93AC70143Q38077799-0AD0060E-0ECF-42BF-8290-6BAF33EB2EF2Q38114863-78A53B68-5DFF-47DB-BAA3-8B979216C731Q38249704-13B00BDC-A8BE-47D3-B387-671ED463DC20Q38255425-A32FBD7A-E7E8-4A7B-9F9F-5ADB3CC29D16Q38368957-683EE6FA-214D-47DF-8B48-695D2A77B5CBQ38569940-8439FB7E-F439-48ED-BA39-4813EE4E0523Q38632762-25132E89-51C6-4C5E-B568-CFBC3B9477D5Q39017229-E89DA157-2C3E-4020-9C05-71D362D95B0AQ40772216-38A26DE3-6C31-44CC-AC62-1AFC1E98115DQ46183977-1A439E0D-9A9F-46D6-AB76-741DF14B8FC5Q46816506-CE324DF7-7A10-4881-9BCD-181C14F9C7CAQ53074365-FFF553F6-0EC3-49C6-ACBA-ACE6C2D61450Q54272801-EE53969E-E810-468B-98B2-3D465679D737Q56627554-1926E5EF-1CC1-4320-B36F-EEFB4A007B8F
P2860
Safety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Safety, tolerability and pharm ...... lmonary arterial hypertension.
@ast
Safety, tolerability and pharm ...... lmonary arterial hypertension.
@en
Safety, tolerability and pharm ...... lmonary arterial hypertension.
@nl
type
label
Safety, tolerability and pharm ...... lmonary arterial hypertension.
@ast
Safety, tolerability and pharm ...... lmonary arterial hypertension.
@en
Safety, tolerability and pharm ...... lmonary arterial hypertension.
@nl
prefLabel
Safety, tolerability and pharm ...... lmonary arterial hypertension.
@ast
Safety, tolerability and pharm ...... lmonary arterial hypertension.
@en
Safety, tolerability and pharm ...... lmonary arterial hypertension.
@nl
P2093
P2860
P1476
Safety, tolerability and pharm ...... ulmonary arterial hypertension
@en
P2093
Gary Layton
Hunter Gillies
Jean-Luc Vachiery
Robert Naeije
Sandrine Huez
P2860
P304
P356
10.1111/J.1365-2125.2010.03831.X
P407
P50
P577
2011-02-01T00:00:00Z